BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 16930846)

  • 1. Dual targeting of epigenetic therapy in cancer.
    Hellebrekers DM; Griffioen AW; van Engeland M
    Biochim Biophys Acta; 2007 Jan; 1775(1):76-91. PubMed ID: 16930846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic regulation of tumor endothelial cell anergy: silencing of intercellular adhesion molecule-1 by histone modifications.
    Hellebrekers DM; Castermans K; Viré E; Dings RP; Hoebers NT; Mayo KH; Oude Egbrink MG; Molema G; Fuks F; van Engeland M; Griffioen AW
    Cancer Res; 2006 Nov; 66(22):10770-7. PubMed ID: 17108113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of epigenetically silenced genes in tumor endothelial cells.
    Hellebrekers DM; Melotte V; Viré E; Langenkamp E; Molema G; Fuks F; Herman JG; Van Criekinge W; Griffioen AW; van Engeland M
    Cancer Res; 2007 May; 67(9):4138-48. PubMed ID: 17483324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiostatic activity of DNA methyltransferase inhibitors.
    Hellebrekers DM; Jair KW; Viré E; Eguchi S; Hoebers NT; Fraga MF; Esteller M; Fuks F; Baylin SB; van Engeland M; Griffioen AW
    Mol Cancer Ther; 2006 Feb; 5(2):467-75. PubMed ID: 16505122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
    Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
    J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic therapy in cancer: molecular background and clinical development of histone deacetylase and DNA methyltransferase inhibitors.
    Schneider-Stock R; Ocker M
    IDrugs; 2007 Aug; 10(8):557-61. PubMed ID: 17665331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic drugs take on cancer.
    Kaiser J
    Science; 2010 Oct; 330(6004):576-8. PubMed ID: 21030620
    [No Abstract]   [Full Text] [Related]  

  • 8. DNA demethylating agents and histone deacetylase inhibitors in hematologic malignancies.
    Fandy TE; Carraway H; Gore SD
    Cancer J; 2007; 13(1):40-8. PubMed ID: 17464245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review-Epigenetic therapy for cancer.
    Saleem M; Abbas K; Manan M; Ijaz H; Ahmed B; Ali M; Hanif M; Farooqi AA; Qadir MI
    Pak J Pharm Sci; 2015 May; 28(3):1023-32. PubMed ID: 26004710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA Methyltransferase Inhibitors and their Therapeutic Potential.
    Zhou Z; Li HQ; Liu F
    Curr Top Med Chem; 2018; 18(28):2448-2457. PubMed ID: 30465505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic approach for angiostatic therapy: promising combinations for cancer treatment.
    Berndsen RH; Abdul UK; Weiss A; Zoetemelk M; Te Winkel MT; Dyson PJ; Griffioen AW; Nowak-Sliwinska P
    Angiogenesis; 2017 May; 20(2):245-267. PubMed ID: 28378227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic therapy for solid tumors: from bench science to clinical trials.
    Juo YY; Gong XJ; Mishra A; Cui X; Baylin SB; Azad NS; Ahuja N
    Epigenomics; 2015; 7(2):215-35. PubMed ID: 25942532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA methyltransferase inhibitors for cancer therapy.
    Brueckner B; Kuck D; Lyko F
    Cancer J; 2007; 13(1):17-22. PubMed ID: 17464242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of DNA methyltransferase inhibitors for the treatment of neoplastic diseases.
    Fandy TE
    Curr Med Chem; 2009; 16(17):2075-85. PubMed ID: 19519382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic tools in potential anticancer therapy.
    Sebova K; Fridrichova I
    Anticancer Drugs; 2010 Jul; 21(6):565-77. PubMed ID: 20436342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytostatic and apoptotic effects of DNMT and HDAC inhibitors in endometrial cancer cells.
    Xu S; Ren J; Chen HB; Wang Y; Liu Q; Zhang R; Jiang SW; Li J
    Curr Pharm Des; 2014; 20(11):1881-7. PubMed ID: 23888960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct monitoring of breast and endometrial cancer cell epigenetic response to DNA methyltransferase and histone deacetylase inhibitors.
    Teixeira SR; Abreu CM; Parkes L; Davies J; Yao S; Sawhney MA; Margarit L; Gonzalez D; Pinto IM; Francis LW; Conlan RS
    Biosens Bioelectron; 2019 Sep; 141():111386. PubMed ID: 31220725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic inhibitors.
    Verma M; Banerjee HN
    Methods Mol Biol; 2015; 1238():469-85. PubMed ID: 25421675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Development of novel epigenetic molecular-targeting agents].
    Sowa Y; Sakai T
    Nihon Rinsho; 2015 Aug; 73(8):1263-7. PubMed ID: 26281676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA hypermethylation as a chemotherapy target.
    Ren J; Singh BN; Huang Q; Li Z; Gao Y; Mishra P; Hwa YL; Li J; Dowdy SC; Jiang SW
    Cell Signal; 2011 Jul; 23(7):1082-93. PubMed ID: 21345368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.